AJP delivered 13% sales CAGR from Dec'18 to Dec'21, led by steady traction in existing therapies and ramp-up in newly added therapies and the Trade Generics segment. It delivered a sales growth of 23% YoY to INR7.3b (30% of sales) in 9MFY22. With the easing of COVID-19 cases, doctor-patient connectivity has significantly improved, particularly in the Ophthalmology/Dermatology segment (39% of DF sales in 9MFY22). This bodes well for better growth prospects for AJP. This, along with enhanced marketing efforts in the Cardiology segment (~41% of DF sales in 9MFY22)...